Economic evaluation of donepezil in moderate to severe Alzheimer disease.
van Hout
Hein P J
HP
Bosmans
Judith E
JE
Stalman
Wim A B
WA
D000544:Alzheimer Disease / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D000077265:Donepezil; D006801:Humans; D007189:Indans / Q000191:economics* / Q000627:therapeutic use*; D009480:Neuropharmacology / Q000191:economics* / Q000592:standards*; D018697:Nootropic Agents / Q000191:economics / Q000627:therapeutic use; D010880:Piperidines / Q000191:economics* / Q000627:therapeutic use*; D010919:Placebos / Q000191:economics / Q000627:therapeutic use; D015203:Reproducibility of Results
D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D010919:Placebos; D000077265:Donepezil